[COVID-19 treated with oral Nirmatrelvir-Ritonavir in 3 children].
Zhonghua Er Ke Za Zhi
; 60(11): 1168-1171, 2022 Nov 02.
Article
in Chinese
| MEDLINE | ID: covidwho-2099942
ABSTRACT
Objective:
To summarize the application experience and the therapeutic effect of Nirmatrelvir-Ritonavir (trade name Paxlovid) for COVID-19 in children.Methods:
A retrospective analysis was performed on the clinical data, including collecting the clinical manifestations and clinical outcomes, dynamically monitoring the blood routine, hepatic and renal function and SARS-CoV-2 nucleic acid results, and observing the related side effects during the treatment, etc, of 3 cases with COVID-19 treated with Paxlovid admitted to Shanghai Children's Hospital (designated referral hospital for SARS-CoV-2 infection in Shanghai) from May 1st to June 1st, 2022.Results:
The 3 cases were 12, 14, 17 years of age, among which 2 cases were males, 1 case was female. All 3 cases were mild cases with underlying diseases and risk of developing into severe COVID-19, with symptoms of high fever, sore throat and dry cough. The treatment of Paxlovid at 3rd day of symptom onset contributed to the symptom-free after 1-2 days and negative results of SARS-CoV-2 nucleic acid after 2-4 days. All patients had no adverse manifestations of gastrointestinal tract and nervous system but a case had little skin rashes, which recovered after the withdrawal of Paxlovid. Three cases had normal hepatic and renal function during the Paxlovid treatment. At 3 months after discharge, no clinical manifestations of post-COVID syndrome were found in all 3 cases.Conclusion:
Paxlovid was effective and relatively safe in the treatment of 3 children with COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Nucleic Acids
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Child
/
Female
/
Humans
/
Male
Country/Region as subject:
Asia
Language:
Chinese
Journal:
Zhonghua Er Ke Za Zhi
Year:
2022
Document Type:
Article
Affiliation country:
Cma.j.cn112140-20220701-00608
Similar
MEDLINE
...
LILACS
LIS